Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 14 new employees, totaling 9,502 shares of company common stock. These grants were made under the company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for January 2, 2025. The awards were approved by the compensation committee of Incyte's board of directors as an inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments of 25% each, contingent upon continued employment with the company.
Incyte (INCY) ha annunciato l'assegnazione di premi in forma di azioni riservate (RSU) a 14 nuovi dipendenti, per un totale di 9.502 azioni ordinarie dell'azienda. Questi premi sono stati concessi secondo il Piano di Incentivazione Azionaria 2024 dell'azienda, con la data di concessione e quella di inizio maturazione fissate per il 2 gennaio 2025. I premi sono stati approvati dal comitato per le retribuzioni del consiglio di amministrazione di Incyte come incentivo per i nuovi dipendenti che si uniscono all'azienda, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Le RSU matureranno in quattro rate annuali uguali del 25% ciascuna, a condizione di continuare a lavorare con l'azienda.
Incyte (INCY) ha anunciado la concesión de premios en acciones restringidas (RSUs) a 14 nuevos empleados, con un total de 9,502 acciones ordinarias de la compañía. Estas concesiones se realizaron bajo el Plan de Incentivo de Acciones de 2024 de la compañía, con la fecha de concesión y la fecha de inicio de la adquisición establecidas para el 2 de enero de 2025. Los premios fueron aprobados por el comité de compensación de la junta directiva de Incyte como un incentivo para los nuevos empleados que se unen a la compañía, en cumplimiento con la Regla de Cotización Nasdaq 5635(c)(4). Las RSUs se adquirirán en cuatro cuotas anuales iguales del 25% cada una, condicionadas a la continuidad del empleo en la compañía.
Incyte (INCY)는 14명의 신입 사원에게 총 9,502주의 회사 보통주에 대한 제한 주식 단위(RSU) 상여를 부여했다고 발표했습니다. 이 상여는 2024 유인 주식 인센티브 계획에 따라 이루어졌으며, 부여일 및 권리행사 시작일은 2025년 1월 2일로 설정되었습니다. 이 상여는 Incyte의 이사회 보상 위원회에 의해 신입 사원들에 대한 유인책으로 승인되었으며, 이는 Nasdaq 상장 규칙 5635(c)(4)에 따른 것입니다. RSU는 회사에 지속적으로 근무하는 조건으로 25%씩 네 번의 동일한 연간 할부로 취득됩니다.
Incyte (INCY) a annoncé l'octroi de primes en unités d'actions restreintes (RSUs) à 14 nouveaux employés, totalisant 9 502 actions ordinaires de la société. Ces attributions ont été faites dans le cadre du Plan d'Incitation à l'Action 2024 de la société, avec la date d'octroi et la date de début de l'acquisition fixées au 2 janvier 2025. Les attributions ont été approuvées par le comité des rémunérations du conseil d'administration d'Incyte comme une incitation pour les nouveaux employés rejoignant l'entreprise, conformément à la règle d'inscription Nasdaq 5635(c)(4). Les RSUs seront acquises en quatre versements annuels égaux de 25 % chacun, sous réserve de la continuité de l'emploi dans l'entreprise.
Incyte (INCY) hat die Gewährung von Restriktiven Aktienoptionsrechten (RSUs) an 14 neue Mitarbeiter bekannt gegeben, insgesamt 9.502 Aktien des Unternehmens. Diese Gewährungen wurden im Rahmen des Aktienincentiveplans 2024 des Unternehmens vorgenommen, wobei sowohl das Gewährungsdatum als auch das Datum des Beginns der Vesting am 2. Januar 2025 festgelegt wurden. Die Zulassungen wurden vom Vergütungsausschuss des Vorstands von Incyte als Anreiz für neu eintretende Mitarbeiter genehmigt, gemäß der Nasdaq-Listing-Regel 5635(c)(4). Die RSUs werden in vier gleichen jährlichen Raten von jeweils 25% fällig, vorausgesetzt, dass die Beschäftigung im Unternehmen fortgesetzt wird.
- Implementation of employee retention strategy through equity-based compensation
- Successful attraction of new talent with 14 new hires
- Potential dilution of existing shareholders' equity due to new share issuance
Each RSU vests as to
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108900343/en/
Media
media@incyte.com
Investors
ir@incyte.com
Source: Incyte
FAQ
How many shares of RSUs did Incyte (INCY) grant to new employees in January 2025?
What is the vesting schedule for Incyte's (INCY) January 2025 RSU grants?
Under which plan were Incyte's (INCY) January 2025 RSU grants made?
What regulatory rule governs Incyte's (INCY) January 2025 RSU grants?
